ClinicalTrials.gg

Program

glepaglutide

Also written as “Glepaglutide”, “ZP1848” and “Glepaglutide 10 mg”.

Its studies are mostly in Short Bowel Syndrome · Renal Insufficiency · Inflammatory Bowel Diseases, led by Zealand Pharma.

Furthest: phase 3, since Sep 17, 201811 company-led studies, 2 open or runningNext primary completion: Sep 18, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zealand Pharma112 open or runningphase 3since Sep 17, 2018Mar 23, 2009Sep 18, 2028phase 3 · NCT07228403

Also a collaborator on its studies: larix-a-s.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 23, 2009First study: phase 1 study in Inflammatory Bowel DiseasesFirst studyNCT00868660 · 66 enrolled · United States
  2. Feb 12, 2016Phase 2 study in Short Bowel SyndromeNCT02690025 · 18 enrolled · Denmark
  3. Sep 5, 2017Phase 1 study in Healthy SubjectsNCT03279302 · 75 enrolled · United States
  4. Sep 17, 2018Phase 3 study in Short Bowel SyndromeNCT03690206 · 106 enrolled · United States, Belgium, Canada and more
  5. Mar 28, 2019Phase 3 study in Short Bowel SyndromeNCT03905707 · 150 enrolled · United States, Belgium, Canada and more
  6. Nov 25, 2019Phase 1 study in Renal InsufficiencyNCT04178447 · 16 enrolled · Hungary, Poland
  7. Mar 20, 2020Phase 1 study in HealthyNCT04318743 · 85 enrolled · Netherlands
  8. Apr 22, 2021Phase 3 study in Short Bowel SyndromeNCT04881825 · 84 enrolled · United States, Belgium, Denmark and more
  9. Jul 14, 2021Phase 3 study in Short Bowel SyndromeNCT04991311 · 12 enrolled · Denmark
  10. Sep 26, 2025Phase 3 study in Short Bowel SyndromeNCT07197944 · 90 planned · United States, Austria, Belgium and more
  11. Nov 13, 2025Phase 3 study in Short Bowel SyndromeNCT07228403 · 28 enrolled · United States, Belgium, Canada and more

Ahead

  1. Sep 18, 2028Primary completion: phase 3 study in Short Bowel SyndromeNCT07228403
  2. Oct 23, 2028Primary completion: phase 3 study in Short Bowel SyndromeNCT07197944

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07228403Short Bowel Syndrome · United States, Belgium, Canada and more3Active, not recruitingSep 18, 202828
NCT07197944Short Bowel Syndrome · United States, Austria, Belgium and more3RecruitingOct 23, 202890
NCT04991311Short Bowel Syndrome · Denmark3CompletedFeb 2, 202312
NCT04881825Short Bowel Syndrome · United States, Belgium, Denmark and more3CompletedApr 30, 202684
NCT04318743Healthy · Netherlands1CompletedJun 10, 202185
NCT04178447Renal Insufficiency · Hungary, Poland1CompletedJul 14, 202016
NCT03905707Short Bowel Syndrome · United States, Belgium, Canada and more3CompletedApr 30, 2026150
NCT03690206Short Bowel Syndrome · United States, Belgium, Canada and more3CompletedJul 26, 2022106
NCT03279302Healthy Subjects · United States1CompletedDec 18, 201775
NCT02690025Short Bowel Syndrome · Denmark2CompletedMay 201718
NCT00868660Inflammatory Bowel Diseases · United States1CompletedFeb 201066

How it is read

Names in the registry

  • “Glepaglutide”, 6 entries
  • “glepaglutide”, 2 entries
  • “ZP1848”, 2 entries
  • “Glepaglutide 10 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.